Definium Therapeutics (DFTX) vs Glass House Brands Subordinate Voting Shares (GLAS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed Glass House Brands Subordinate Voting Shares (GLAS) over the past year, gaining 193.1% versus a loss of 36.7%. Over five years, GLAS leads with a +2.7% price change compared with -0.5% for DFTX. Definium Therapeutics is the larger company by market cap ($4.71 billion vs $483.5 million), about 9.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DFTX | GLAS |
|---|---|---|
| Share price | $35.09 | $5.13 |
| Market cap | $4.71B | $483.46M |
| 1-day change | -1.49% | -0.58% |
| YTD return | +162.06% | -42.03% |
| 1-year return | +193.15% | -36.67% |
| 5-year return | -0.45% | +2.70% |
| Forward P/E | — | 22.80 |
| EPS (TTM) | $-3.43 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-183.79M | — |
| 52-week high | $49.70 | $13.93 |
| 52-week low | $10.47 | $4.97 |
| Distance from 52-week high | -29.40% | -63.17% |
| Analyst consensus | none | none |
| Avg. price target upside | +104.19% | +211.89% |
| Average volume | 2.15M | 735.63K |
| Shares outstanding | 134.37M | 88.00M |
| Employees | 105 | 357 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Definium Therapeutics is about 9.8 times larger than Glass House Brands Subordinate Voting Shares by market value ($4.71B vs $483.46M).
- DFTX has outperformed GLAS by 229.8 percentage points over the past year.
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
About Glass House Brands Subordinate Voting Shares
GLAS stock →Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods.
Health Care · Medicinal Chemicals and Botanical Products · 357 employees
DFTX vs GLAS FAQ
Which is bigger, Definium Therapeutics or Glass House Brands Subordinate Voting Shares?
Definium Therapeutics (DFTX) is larger, with a market capitalization of $4.71B compared with $483.46M for Glass House Brands Subordinate Voting Shares (GLAS).
Which stock has performed better over the past year, DFTX or GLAS?
DFTX returned +193.15% over the past 12 months, compared with -36.67% for GLAS (price return, excluding dividends). Past performance does not predict future results.
Are Definium Therapeutics and Glass House Brands Subordinate Voting Shares in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.